Well-versed in regulation


Well-versed in regulation

25.07.2016 - Swedish rare disease expert Wilson Therapeutics AB has appointed global regulatory executive Rick Lilley as Chief Regulatory Officer.

Lilley, who received his BSc in microbiology and genetics as well as his PhD in molecular genetics from Queen Mary College, University of London, has held senior positions in regulatory affairs and drug development in Europe, Japan and USA for the last three decades. Most recently, he served as Senior VP and Head of Global Regulatory Affairs at US pharma company Vertex Pharmaceuticals. At Vertex, he was responsible for the global filings for the breakthrough orphan drug Orkambi. Prior to that, Lilley was VP and Head of Global Regulatory Affairs at Belgian biopharma UCB. He has also held senior regulatory positions at Johnson & Johnson, Shire and AstraZeneca.


20.07.2016 Eduardo Bravo takes over as President of the Board of Directors of European Biopharmaceutical Enterprises (EBE). Bravo is CEO of Belgian stem cell-based drug developer TiGenix NV.


EBE, the European trade association that represents European biopharmaceutical companies of all sizes, appointed Bravo in June. He had already served as Vice President of EBE for some time.

Bravo, who holds a degree in Business Administration and an MBA (INSEAD), has been CEO of TiGenix since May 2011. He joined the Belgian company in 2005. Prior to that, he held several senior management positions at Sanofi-Aventis, including Vice President for Latin America. He was also general manager for Belgium. Prior to his tenure at Sanofi-Aventis, Bravo spent seven years at SmithKline Beecham in commercial positions both nationally and internationally. 


18.07.2016 Uwe Meya is taking over as Chief Medical Officer at Barcelona-based orphan drug developer Minoryx Therapeutics. Meya will advance the clinical development of Minoryx’ lead candidate MIN-102 for adrenoleukodystrophy.

© Minoryx

Meya, a neurologist and psychiatrist, joins Minoryx Therapeutics from Swiss Lupin Atlantis Holdings SA, where he was responsible for clinical strategy and implementation of studies with new clinical entities in various indications, including neurodegenerative disorders. 

Previously, he worked at Synosia Therapeutics, Roche and Novartis. Meya received his medical degree as well as his doctorate in psychiatry from the University of Aachen (Germany). He is a member of the European College of Neuropsychopharmacology as well as the International Parkinson and Movement Disorder Society and is a founding member of the International College of Geriatric Psychoneuropharmacology.


13.07.2016 In July, British research service provider Envigo appointed Adrian Hardy as President and CEO. Hardy will also join Envigo’s Board of Directors.

© Envigo

Hardy, who holds a BSc in Human Biology from King’s College London and a PhD in Developmental Biology from University College London, has been with Envigo since 2002. He held various roles in Sales, Strategic Marketing and Operations. Most recently, Hardy held the position of COO. 


11.07.2016 US-Dutch medical device company EndoStim, developer of neurostimulation therapy for gastroesophageal reflux disease, has named ­Rohan Hoare as president and CEO. He succeeds founder Bevil Hogg, who will continue to serve the company as a consultant.

© EndoStim

Hoare, who holds a Master of Arts and a PhD in physics from Harvard University, was previously president of the Neuromodulation business unit of Livanova, the London-based company formed by the merger of Cyberonics and Sorin Group.


06.07.2016 Antibody veteran David Chiswell, Interim CEO and Chair of Cambridge-based antibody developer Kymab, is taking over at the company’s helm for good. Kymab’s new old CEO is stepping down from his role as Chairman, however.

© Kymab

Chiswell was one of the co-founders of Cambridge Antibody Technology (CAT), where he also served as CEO from 1996 till 2002. Chiswell currently serves as chairman of Albireo Pharma, Swedish developer of treatments for gastrointestinal disease, and is a director of Austria’s antibiotics specialist Nabriva Therapeutics. He is also a former chairman of the UK BioIndustry association (BIA). In 2006, he was awarded the Most Excellent Order of the British Empire (OBE) by Her Majesty the Queen for services to the biotechnology industry.


04.07.2016 The EMA’s Committee for Medicinal Products for Veterinary Use (CVMP) has unanimously appointed David Murphy from Ireland as its new Chair for the next three years. Murphy, a qualified veterinarian, is the Veterinary Assessment Manager at the Health Products Regulatory Authority in Ireland.


Murphy has been a CVMP member since 2009 and has served as Vice-Chair and Chair of the Strategic Planning Group. He holds a PhD from the University of Glasgow in Equine Medicine. 

The mandate covers three years starting in June 2016. The CVMP will elect a new Vice-chair in July.


01.07.2016 Torsten Hombeck will take charge of the commercial activities and the general strategy of Promethera Biosciences. The Belgian cell therapy specialist appointed Hombeck as Chief Commercial and Strategy Officer.

© Promethera

Hombeck was Co-CEO and Chief Business Officer at Cytonet GmbH & Co KG, spokesperson, Co-CEO and Chief Financial Officer at Agennix AG and Chief Financial officer at GPC Biotech AG. He has extensive experience in clinical and commercial drug development, as well as with regulatory filings for various drug development product candidates and financings of private and public companies including IPOs and follow ons. He received an MBA and Ph.D. in finance from the European Business School University of Business and Law in Oestrich-Winkel, Germany.

Promethera also appointed Christof Hettich as new Chairman of the Board. 


29.06.2016 Palma de Mallorca-based Sanifit, an expert for calcification disorders, has appointed Preston Klassen as its Chief Medical Officer. Klassen will also serve as President of Sanifit’s newly launched US subsidiary in San Diego.

© Sanifit

Klassen was most recently Executive Vice President, Head of Global Development at Orexigen Therapeutics. He previously held several positions at Amgen, Inc, including Therapeutic Area Head for Nephrology. Before that, Klassen was a faculty member in the Division of Nephrology at Duke University Medical Center. He received his M.D. from the University Of Nebraska College Of Medicine and M.H.S. degree from Duke University.


27.06.2016 Harriet Fear, CEO of not-for-profit One Nucleus, has been appointed a Member of the Order of the British Empire in the Queen’s Birthday 2016 Honours List. The award recognises her services to the life science sector.

© One Nucleus

Fear previously worked as a Diplomat with the British Foreign Office for 21 years serving in over 17 countries around the globe. Half her career was spent in the commercial field, latterly heading UK Trade & Investments’ national life sciences trade team for over 5 years. During her varied Foreign Office career she was Deputy Ambassador three times, Private Secretary to the Minister for Europe, led an evacuation of Brits out of the Congo and worked in Khymer Rouge territory with Scotland Yard on a hostage crisis.

Fear took over as Chief Executive at One Nucleus, an international membership organisation for life science and healthcare companies, in 2009 and was responsible for merging the former organisation ERBI with the London Biotechnology Network. 


24.06.2016 UK biotech Bicycle Therapeutics has established US operations in Cambridge (MA). Rosamund Deegan, appointed to the newly established role of President and Chief Business Officer, will be responsible for leading the company’s US business development and for establishing a team in the US.

© Bicycle Therapeutics

Bicycle Therapeutics is a biotechnology company developing a new class of therapeutics based on its proprietary bicyclic peptides platform, headquartered in Cambridge, UK. Deeagan joins from Trevena, where she  held the position of Senior VP Business development and Operations. Previously, she worked at GlaxoSmithKline. Deegan graduated from Cambridge University and holds an MBA from French business school INSEAD. 

1/37Nächste Seite


Current issue

All issues

Product of the week


Stock list

All quotes


  • MOLOGEN (D)1.75 EUR16.67%
  • RENEURON (UK)3.15 GBP5.00%


  • VECTURA (UK)148.80 GBP-4.25%


  • PROTHENA PLC (IE)52.22 USD47.2%
  • DBV TECHNOLOGIES (F)64.40 EUR26.3%


  • MOLOGEN (D)1.75 EUR-30.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SAREUM HOLDINGS (UK)0.62 GBP-19.5%


  • KARO BIO (S)29.80 SEK1774.2%
  • NICOX (F)11.20 EUR474.4%
  • SAREUM HOLDINGS (UK)0.62 GBP158.3%


  • BB BIOTECH (D)45.00 EUR-84.5%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 25.07.2016


All Events